Edition:
India

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

5,011JPY
19 Apr 2019
Change (% chg)

¥48 (+0.97%)
Prev Close
¥4,963
Open
¥5,000
Day's High
¥5,085
Day's Low
¥4,990
Volume
1,188,700
Avg. Vol
2,062,770
52-wk High
¥5,794
52-wk Low
¥3,277

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.95
Market Cap(Mil.): ¥3,518,823.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 1.41

Financials

  4568.T Industry Sector
P/E (TTM): 48.42 57.23 57.80
EPS (TTM): 102.49 -- --
ROI: 4.18 12.21 11.82
ROE: 5.46 13.15 12.64

MEDIA-India's Ex-Ranbaxy promoters diverted funds, Daiichi Sankyo tells Supreme Court - Times Of India

- Note: Reuters has not verified this story and does not vouch for its accuracy

12 Apr 2019

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

29 Mar 2019

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca Plc will pay up to $6.9 billion to work with Daiichi Sankyo Co Ltd on a hotly-tipped experimental treatment for breast cancer, in a direct challenge to the world's biggest cancer drug maker Roche.

29 Mar 2019

Nikkei up on U.S.-China trade talk optimism; Daiichi Sankyo jumps

TOKYO, March 29 Japan's Nikkei rose on Friday on optimism about the latest round of U.S.-China trade talks, with cyclical sectors such as shipping and machinery advancing on the last day of the Japanese fiscal year.

29 Mar 2019

REFILE-Nikkei rises on optimism over U.S.-China trade talks; Daiichi Sankyo jumps

* Nikkei has shed 2.1 for week, dropped 1 pct for month so far

29 Mar 2019

UPDATE 1-Daiichi Sankyo, AstraZeneca sign $6.9 bln cancer drug deal

* Daiichi shares jump 16 pct, hit daily limit (Adds share price, executive comment)

29 Mar 2019

AstraZeneca and Daiichi Sankyo to jointly develop cancer drug

March 28 British drugmaker AstraZeneca Plc said late on Thursday it entered into a collaboration deal with Daiichi Sankyo Co Ltd of Japan to develop trastuzumab deruxtecan, a proprietary antibody-drug conjugate for cancer treatment.

29 Mar 2019

Japan's Daiichi Sankyo explores OTC drugs business sale, hires JPMorgan -sources

TOKYO Japan's Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs (OTC) business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters.

01 Mar 2019

UPDATE 1-Japan's Daiichi Sankyo explores OTC drugs business sale, hires JPMorgan -sources

TOKYO, March 1 Japan's Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs (OTC) business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters.

01 Mar 2019

Japan's Daiichi Sankyo exploring sale of OTC business, hires JP Morgan -sources

TOKYO, March 1 Japan's Daiichi Sankyo Co is exploring the sale of its over-the-counter drugs business and has hired JPMorgan to advise on the potential deal, several people with knowledge of the matter told Reuters.

01 Mar 2019

Earnings vs. Estimates